TuHURA Biosciences, Inc. ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results